SATSUMA PHARMACEUTICALS, INC. Inactive Instrument
Satsuma Pharmaceuticals, Inc.
Equities
STSA
US80405P1075
Biotechnology & Medical Research
Presenter SpeechJohn Kollins (Executives)Thank you. I'm John Kollins. I'm the President and CE...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.90% | 114B | |
| +11.47% | 104B | |
| -12.65% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -3.02% | 17.89B | |
| +8.37% | 14.28B | |
| +35.08% | 12.55B |
